Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS

24 Oct 2026 0 comments

Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.

Source: NeurologyLive Published 23 Oct 2026 Imported 23 Oct 2026 Relevancy: 85%

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment